Know Cancer

or
forgot password

Measurement of Angiogenic Related Growth Factors in Urine and Blood From Patients With Multivessel Pulmonary Vein Stenosis


N/A
N/A
18 Years
Not Enrolling
Both
Multivessel Pulmonary Vein Stenosis

Thank you

Trial Information

Measurement of Angiogenic Related Growth Factors in Urine and Blood From Patients With Multivessel Pulmonary Vein Stenosis


Patients identified at the time of presentation to their cardiologist will be asked to
provide a urine sample for analysis. If blood is being drawn for other clinical tests, an
extra vial of blood will be collected for measurement of bFGF, VEGF, angiopoietin 1&2 and
ephrin. At the time of blood draws, approximately 4 cc's of heparin blood will be obtained
and processed as detailed below. Blood and/or urine samples will be coordinated through the
data manager and will be performed only when blood is being obtained for other reasons.
Initially, blood samples will be sent to Lab Control, spun down, and the plasma isolated.
Plasma will be coded, then frozen at -200C in the research lab. Urine samples will be
aliquoted into vials and stored at -20 until further analysis.

All patient information will be kept confidential. Individual results will not be provided
to patients. Identifiers to patient information will be maintained. No identifying patient
information will be used in publications that might result from these studies. Information
to be collected by the data manager will include age, sex, date of diagnosis and
interventions.

The specific aim is to assess angiogenic growth factor concentrations in urine and blood
from patients with both congenital and acquired multivessel pulmonary vein stenosis.


Inclusion Criteria:



- Diagnosis can be based on clinical and radiographic grounds or at the time of biopsy
or prior surgical procedures. The diagnosis must be consistent with multivessel
pulmonary stenosis.

- There must be evidence of severe pulmonary vein stenosis in at least two pulmonary
veins.

- Must give written informed consent according to institutional guidelines

Exclusion Criteria:

- Mechanism of pulmonary venous obstruction due to obvious anatomic cause, such as
extrinsic compression

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Principal Investigator

Mark W Kieran, MD,PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Dana-Farber Cancer Institute

Authority:

United States: Institutional Review Board

Study ID:

CH X00-09-050

NCT ID:

NCT00215059

Start Date:

August 2000

Completion Date:

July 2012

Related Keywords:

  • Multivessel Pulmonary Vein Stenosis
  • angiogenic related growth factor
  • Constriction, Pathologic

Name

Location

Children's Hospital BostonBoston, Massachusetts  02115
Dana Farber Cancer InstituteBoston, Massachusetts  02115